Related references
Note: Only part of the references are listed.Use of granulocyte colony-stimulating factor in patients with severe sepsis or septic shock
Rima A. Mohammad
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2010)
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis
Todd W. Rice et al.
CRITICAL CARE MEDICINE (2010)
Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis
Mark Tidswell et al.
CRITICAL CARE MEDICINE (2010)
PROWESS-SHOCK TRIAL: A PROTOCOL OVERVIEW AND PERSPECTIVES
Eliezer Silva et al.
SHOCK (2010)
IL-1β Processing in Host Defense: Beyond the Inflammasomes
Mihai G. Netea et al.
PLOS PATHOGENS (2010)
The Pathophysiology of Septic Shock
O. Okorie Nduka et al.
CRITICAL CARE CLINICS (2009)
Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: Results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial
R. Phillip Dellinger et al.
CRITICAL CARE MEDICINE (2009)
Early Use of Polymyxin B Hemoperfusion in Abdominal Septic Shock The EUPHAS Randomized Controlled Trial
Dinna N. Cruz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Intensive Insulin Therapy in Critically Ill Patients: NICE-SUGAR or Leuven Blood Glucose Target?
Greet Van den Berghe et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Intensive versus Conventional Glucose Control in Critically Ill Patients
S. Finfer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Innate Immune Responses to Danger Signals in Systemic Inflammatory Response Syndrome and Sepsis
A. Castellheim et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2009)
Pro- and Synbiotics to Control Inflammation and Infection in Patients With Multiple Injuries
Evangelos J. Giamarellos-Bourboulis et al.
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE (2009)
Effect of short-term intralipid infusion on the immune response during low-dose endotoxemia in humans
Rikke Krogh-Madsen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2008)
Experimental Therapeutic Strategies for Severe Sepsis Mediators and Mechanisms
William R. Parrish et al.
NEURAL SIGNALING: OPPORTUNITIES FOR NOVEL DIAGNOSTIC APPROACHES AND THERAPIES (2008)
Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia
Evangelos J. Giamarellos-Bourboulis et al.
CLINICAL INFECTIOUS DISEASES (2008)
The Compensatory Anti-inflammatory Response Syndrome (CARS) in Critically Ill Patients
Nicholas S. Ward et al.
CLINICS IN CHEST MEDICINE (2008)
Early enteral supplementation with key pharmaconutrients improves Sequential Organ Failure Assessment score in critically ill patients with sepsis: Outcome of a randomized, controlled, double-blind trial
Richard J. Beale et al.
CRITICAL CARE MEDICINE (2008)
Randomized, double-blind, placebo-controlled trial of granulocyte colony-stimulating factor in patients with septic shock
Dianne P. Stephens et al.
CRITICAL CARE MEDICINE (2008)
Effect of insulin therapy on coagulation and fibrinolysis in medical intensive care patients
Lies Langouche et al.
CRITICAL CARE MEDICINE (2008)
Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: Consensus statements from an international task force by the American College of Critical Care Medicine
Paul E. Marik et al.
CRITICAL CARE MEDICINE (2008)
Immunomodulatory therapies for sepsis: unexpected effects with macrolides
Evangelos J. Giamarellos-Bourboulis
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2008)
Thymosin alpha(1)- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria
Ying Zhang et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Diversity of interferon γ and granulocyte-macrophage colony-stimulating factor in restoring immune dysfunction of dendritic cells and macrophages during polymicrobial sepsis
Stefanie B. Flohe et al.
MOLECULAR MEDICINE (2008)
Hydrocortisone therapy for patients with septic shock
Charles L. Sprung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Intensive insulin therapy and pentastarch resuscitation in severe sepsis
Frank M. Brunkhorst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Glutamine as a modulator of the immune system of critical care patients:: Effect on Toll-like receptor expression.: A preliminary study
Jon Perez-Barcena et al.
NUTRITION (2008)
Tissue factor as an initiator of coagulation and inflammation in the lung
Tom van der Poll
CRITICAL CARE (2008)
Score-based immunoglobulin G therapy of patients with sepsis:: The SBITS study
Karl Werdan et al.
CRITICAL CARE MEDICINE (2007)
Immunoparalysis after multiple trauma
Sven K. Tschoeke et al.
INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED (2007)
The T in trauma: the helper T-cell response and the role of immunomodulation in trauma and burn patients
Andrew C. Miller et al.
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE (2007)
Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock
K. Georg Kreyrnann et al.
CRITICAL CARE MEDICINE (2007)
A novel selective extracorporeal intervention in sepsis: Immunoadsorption of endotoxin, interleukin 6, and complement-activating product 5A
Joerg C. Schefold et al.
SHOCK (2007)
Association between high levels of blood macrophage migration inhibitory factor, inappropriate adrenal response, and early death in patients with severe sepsis
Marieke Emonts et al.
CLINICAL INFECTIOUS DISEASES (2007)
Endogenous anticoagulant therapy for sepsis
C. J. Wiedermann
INTERNIST (2007)
Adrenal function in sepsis: The retrospective Corticus cohort study
Diane Lipiner-Friedman et al.
CRITICAL CARE MEDICINE (2007)
A Phase II, double-blind, placebo-controlled, ascending-dose study of eritoran (E5564), a lipid a antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass
Elliott Bennett-Guerrero et al.
ANESTHESIA AND ANALGESIA (2007)
DAMPs, PAMPs and alarmins: all we need to know about danger
Marco E. Bianchi
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
Selenium in Intensive Care (SIC):: Results of a prospective. randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock
Matthias W. A. Angstwurm et al.
CRITICAL CARE MEDICINE (2007)
Effects of high doses of selenium, as sodium selenite, in septic shock: A placebo-controlled, randomized, double-blind, phase II study
Xavier Forceville et al.
CRITICAL CARE (2007)
Recombinant bactericidal/permeability-increasing protein rBPI(21) protects against pneumococcal disease
Amit Srivastava et al.
INFECTION AND IMMUNITY (2007)
Circulating high-mobility group box 1 (HMGB1) concentrations are elevated in both uncomplicated pneumonia and pneumonia with severe sepsis
Derek C. Angus et al.
CRITICAL CARE MEDICINE (2007)
Benefits of a synbiotic formula (Synbiotic 2000Forte®) in critically ill trauma patients:: Early results of a randomized controlled trial
Katerina Kotzampassi et al.
WORLD JOURNAL OF SURGERY (2006)
Effects of enteral feeding with eicosapentaenoic acid, γ-linolenic acid, and antioxidants in mechanically ventilated patients with severe sepsis and septic shock
Alessandro Pontes-Arruda et al.
CRITICAL CARE MEDICINE (2006)
Safety and efficacy of affinity-purified, anti-tumor necrosis factor-α, ovine fab for injection (CytoFab) in severe sepsis
Todd W. Rice et al.
CRITICAL CARE MEDICINE (2006)
Monocyte HLA-DR and interferon-gamma treatment in severely injure reappraisal more patients - A critical reappraisal more than a decade later
M Turina et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2006)
Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae
EJ Giamarellos-Bourboulis et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Benefit of an enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with acute lung injury
P Singer et al.
CRITICAL CARE MEDICINE (2006)
Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa
EJ Giamarellos-Bourboulis et al.
BMC INFECTIOUS DISEASES (2006)
Intensive insulin therapy in the medical ICU
G Van den Berghe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock
Q Zhao et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis
Christopher Gonano et al.
CRITICAL CARE (2006)
Dyotyecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment
JL Vincent et al.
CRITICAL CARE MEDICINE (2005)
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
E Abraham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Removal of inflammatory cytokines and endotoxin by veno-venous continuous renal replacement therapy for burned patients with sepsis
YZ Peng et al.
BURNS (2005)
Monocyte anergy is present in patients with severe acute pancreatitis and is significantly alleviated by granulocyte-macrophage colony-stimulating factor and interferon-γ in vitro
ML Kylanpaa et al.
PANCREAS (2005)
Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone
EG Vázquez et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2005)
Tifacogin, Recombinant Tissue Factor Pathway Inhibitor
Robina Matyal et al.
INTERNATIONAL ANESTHESIOLOGY CLINICS (2005)
Interleukin-10 blunts the human inflammatory response to lipopolysaccharide without affecting the cardiovascular response
A Kumar et al.
CRITICAL CARE MEDICINE (2005)
Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli
EJ Giamarellos-Bourboulis et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2005)
Clarithromycin: Immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli
EJ Giamarellos-Bourboulis et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2005)
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock
RP Dellinger et al.
CRITICAL CARE MEDICINE (2004)
Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis
JA Nick et al.
BLOOD (2004)
CD14 receptor occupancy in severe sepsis:: Results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14)
K Reinhart et al.
CRITICAL CARE MEDICINE (2004)
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: Data from the PROWESS trial
JF Dhainaut et al.
INTENSIVE CARE MEDICINE (2003)
Inhibition of endotoxin response by E5564, a novel toll-like receptor 4-directed endotoxin antagonist
M Mullarkey et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia
JA Martínez et al.
CLINICAL INFECTIOUS DISEASES (2003)
Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock
D Annane et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Clinical trials of immunomodulatory therapies in severe sepsis and septic shock
JL Vincent et al.
CLINICAL INFECTIOUS DISEASES (2002)
Efficacy and safety of recombinant human activated protein C for severe sepsis.
GR Bernard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans
A Verbon et al.
JOURNAL OF IMMUNOLOGY (2001)
A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia
E Bunnell et al.
CRITICAL CARE MEDICINE (2000)
Anti-inflammatory therapies in sepsis and septic shock
BD Freeman et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2000)
Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis
JL Vincent et al.
CRITICAL CARE MEDICINE (2000)
Share Paper
